Naringenin
(Synonyms: (S)-柚皮素) 目录号 : GN10276
Naringenin是一种柑橘类黄酮化合物，能够用于治疗癌症，具有抗氧化和抗炎活性。
Cas No.:480-41-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Naringenin is a citrus flavonoid compound that can be used to treat cancer and has antioxidant and anti-inflammatory activities[1]. Naringenin can increase glucose uptake in muscle cells[2]. Naringenin has anti-dengue virus activity[3].
In vitro, treatment of HepG2 cells with Naringenin (50-300μM) for 24h reduced cell viability in a dose-dependent manner, induced rapid accumulation of p53, increased nuclear damage and the proportion of apoptotic cells, and increased the Bax/Bcl-2 ratio[4]. Treatment of MCF-7, HT-29, and PC-12 cells with Naringenin (50-1000μM) for 24h induced the production of ROS in all cancer cells in a dose-dependent manner[5]. Treatment of A431 cells with Naringenin (50-750μM) for 12h induced the production of intracellular ROS in a dose-dependent manner, increased nuclear condensation and DNA fragmentation, induced cell cycle G0/G1 arrest, and increased caspase-3 activity[6].
In vivo, oral administration of Naringenin (50mg/kg/day; 8 weeks) to treat lead acetate-induced oxidative stress in the liver and kidneys of rats significantly attenuated lead-induced biochemical changes in serum, liver, and kidney tissues and alleviated oxidative stress[7].
References:
[1] Motallebi M, Bhia M, Rajani H F, et al. Naringenin: A potential flavonoid phytochemical for cancer therapy[J]. Life Sciences, 2022, 305: 120752.
[2] Zygmunt K, Faubert B, MacNeil J, et al. Naringenin, a citrus flavonoid, increases muscle cell glucose uptake via AMPK[J]. Biochemical and biophysical research communications, 2010, 398(2): 178-183.
[3] Frabasile S, Koishi A C, Kuczera D, et al. The citrus flavanone naringenin impairs dengue virus replication in human cells[J]. Scientific reports, 2017, 7(1): 41864.
[4] Arul D, Subramanian P. Naringenin (citrus flavonone) induces growth inhibition, cell cycle arrest and apoptosis in human hepatocellular carcinoma cells[J]. Pathology & Oncology Research, 2013, 19: 763-770.
[5] Kocyigit A, Koyuncu I, Dikilitas M, et al. Cytotoxic, genotoxic and apoptotic effects of naringenin-oxime relative to naringenin on normal and cancer cell lines[J]. Asian Pacific journal of tropical biomedicine, 2016, 6(10): 872-880.
[6] Ahamad M S, Siddiqui S, Jafri A, et al. Induction of apoptosis and antiproliferative activity of naringenin in human epidermoid carcinoma cell through ROS generation and cell cycle arrest[J]. PloS one, 2014, 9(10): e110003.
[7] Wang J, Yang Z, Lin L, et al. Protective effect of naringenin against lead-induced oxidative stress in rats[J]. Biological trace element research, 2012, 146: 354-359.
Naringenin是一种柑橘类黄酮化合物，能够用于治疗癌症，具有抗氧化和抗炎活性[1]。Naringenin能够增加肌肉细胞葡萄糖的摄取[2]。Naringenin具有抗登革热病毒活性[3]。
在体外，Naringenin（50-300μM）处理HepG2细胞24h，以剂量依赖性方式降低了细胞活力，诱导了p53快速积累，增加了细胞核损伤和凋亡细胞比例，增加了Bax/Bcl-2比率[4]。Naringenin（50-1000μM）处理MCF-7、HT-29和PC-12细胞24h，以剂量依赖性方式诱导了所有癌细胞中ROS的产生[5]。Naringenin（50-750μM）处理A431细胞12h，以剂量依赖性方式诱导了细胞内ROS的产生，增加了核浓缩和DNA片段化，诱导了细胞周期G0/G1期阻滞，增加了caspase-3活性[6]。
在体内，Naringenin（50mg/kg/day；8周）通过口服治疗醋酸铅诱导的大鼠肝脏和肾脏氧化应激，显著减弱了铅诱导的血清、肝脏和肾脏组织的生化改变，减轻了氧化应激[7]。
| Cell experiment [1]: | |
Cell lines | HepG2 cells |
Preparation Method | Cells were plated in 96-well plates at a density of 8×103 cells per well and incubated for 24h with medium. The cells were rinsed with PBS and grown in a medium containing various concentrations of Naringenin (50, 100, 150, 200, 250, 300μM). The solvent DMSO treated cells were served as control. After 24h of treatment, the medium was removed and replaced by another medium containing MTT solution (1mg/mL), and the cells were incubated for 2h at 37°C. To assess the proportion of viable cells, formazan was solubilized with 150μL DMSO. Plates were then vortexed at room temperature for 30min, and the level of formazan was measured using a spectrophotometer at 575nm. |
Reaction Conditions | 50, 100, 150, 200, 250, 300μM; 24h |
Applications | Naringenin treatment significantly inhibited the proliferation of cells in dose-dependent manner (50-300μM) after 24h of incubation. |
| Animal experiment [2]: | |
Animal models | Sprague–Dawley rats |
Preparation Method | Animals were randomly divided into four groups, six rats in each. (1) In the control group, the rats received lead-free distilled water and physiological saline by oral gavage daily during the course of the experiment; (2) In Naringenin treated group, the animals received Naringenin at a dose of 50mg/kg/day dissolved in 0.1% Tween-80 and distilled water daily by oral gavage; (3) In lead-treated group, the rats received an aqueous solution of lead acetate (Pb(CH3COO)2) at a concentration of 500mg Pb/L as the only drinking fluid and physiological saline by oral gavage daily during the course of the experiment; (4) In lead+Naringenin-treated group, animals received an aqueous solution of lead acetate (500mg Pb/L in drinking water) and received Naringenin at a dose of 50mg/kg/day dissolved in 0.1% Tween-80 and distilled water daily by oral gavage. The experiments lasted for 8 weeks. At the end of the experimental period, blood samples were collected from all animals from the retro-orbital venous plexus under light ether anesthesia. Following the collection of blood samples, all animals were sacrificed; the liver and kidney from each rat were removed, weighed, and washed using chilled saline solution. |
Dosage form | 50mg/kg/day for 8 weeks; p.o. |
Applications | Naringenin markedly attenuated lead-induced biochemical alterations in serum, liver, and kidney tissue. |
References: | |
| Cas No. | 480-41-1 | SDF | |
| 别名 | (S)-柚皮素 | ||
| 化学名 | (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one | ||
| Canonical SMILES | C1C(OC2=CC(=CC(=C2C1=O)O)O)C3=CC=C(C=C3)O | ||
| 分子式 | C15H12O5 | 分子量 | 272.25 |
| 溶解度 | ≥ 13.15mg/mL in DMSO | 储存条件 | Store at-20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.6731 mL | 18.3655 mL | 36.7309 mL |
| 5 mM | 0.7346 mL | 3.6731 mL | 7.3462 mL |
| 10 mM | 0.3673 mL | 1.8365 mL | 3.6731 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet